Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong
Martina McMenamin, Joshua Nealon, Yun Lin, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Modeling transmission of SARS-CoV-2 Omicron in China
Jun Cai, Xiaowei Deng, Juan Yang, et al.
Nature Medicine (2022) Vol. 28, Iss. 7, pp. 1468-1475
Open Access | Times Cited: 251
CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2
Lairun Jin, Zhuopei Li, Xiaoyin Zhang, et al.
Human Vaccines & Immunotherapeutics (2022) Vol. 18, Iss. 6
Open Access | Times Cited: 55
Emerging SARS-CoV-2 variants: Why, how, and what's next?
Yu Chen, Qianyun Liu, Li Zhou, et al.
Cell Insight (2022) Vol. 1, Iss. 3, pp. 100029-100029
Open Access | Times Cited: 47
A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines
Xiao‐Feng He, Jiao Su, Yunan Ma, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 35
SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022
Samuel M. S. Cheng, Chris Ka Pun Mok, Karl CK Chan, et al.
Eurosurveillance (2022) Vol. 27, Iss. 18
Open Access | Times Cited: 34
Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021
Chao Ma, Weiwei Sun, Tingting Tang, et al.
Vaccine (2022) Vol. 40, Iss. 20, pp. 2869-2874
Open Access | Times Cited: 33
Will Omicron finally overpower China’s COVID defences?
Dyani Lewis
Nature (2022) Vol. 604, Iss. 7904, pp. 17-18
Open Access | Times Cited: 31
Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review
Zhonghao Chen, Ying Zhang, Meng Wang, et al.
International Journal of Biological Sciences (2022) Vol. 18, Iss. 12, pp. 4629-4641
Open Access | Times Cited: 30
Efficacy, immunogenicity and safety of COVID-19 vaccines in older adults: a systematic review and meta-analysis
Zejun Li, Shouhuan Liu, Fengming Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 29
Real-world effectiveness of early molnupiravir and nirmatrelvir/ritonavir among hospitalized, non-oxygen-dependent COVID-19 patients on admission during Hong Kong’s Omicron BA.2 wave: an observational study
Carlos King Ho Wong, Ivan Chi Ho Au, Kristy T. K. Lau, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 22
The effectiveness and safety of mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines among individuals with chronic kidney diseases
Franco Wing Tak Cheng, Min Fan, Carlos King Ho Wong, et al.
Kidney International (2022) Vol. 102, Iss. 4, pp. 922-925
Open Access | Times Cited: 20
Strength and durability of antibody responses to BNT162b2 and CoronaVac
Benjamin J. Cowling, Irene Wong, Eunice Y. C. Shiu, et al.
Vaccine (2022) Vol. 40, Iss. 32, pp. 4312-4317
Open Access | Times Cited: 18
Immunogenicity against wild-type and Omicron SARS-CoV-2 after a third dose of inactivated COVID-19 vaccine in healthy adolescents
Daniel Leung, Carolyn A. Cohen, Xiaofeng Mu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 10
Changes in Parents’ COVID-19 Vaccine Hesitancy for Children Aged 3–17 Years before and after the Rollout of the National Childhood COVID-19 Vaccination Program in China: Repeated Cross-Sectional Surveys
Xiaofeng Zhou, Shiyu Wang, Kechun Zhang, et al.
Vaccines (2022) Vol. 10, Iss. 9, pp. 1478-1478
Open Access | Times Cited: 18
Immunogenicity of a Third Dose of BNT162b2 to Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 and the Omicron Variant in Adults Who Received 2 Doses of Inactivated Vaccine
Nancy Leung, Samuel M. S. Cheng, Mario Martín-Sánchez, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 3, pp. e299-e307
Open Access | Times Cited: 17
The effects of vaccination on the disease severity and factors for viral clearance and hospitalization in Omicron-infected patients: A retrospective observational cohort study from recent regional outbreaks in China
Hongru Li, Xiongpeng Zhu, Rongguo Yu, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 15
Covid-19: What can China learn from Hong Kong and Singapore about exiting zero covid?
D.H. Owens, Jane Parry
BMJ (2022), pp. o3043-o3043
Open Access | Times Cited: 9
World-System of Vaccine Distribution
Philipp Köncke, Stefan Schmalz
Journal of World-Systems Research (2024) Vol. 30, Iss. 1, pp. 195-222
Open Access | Times Cited: 1
COVID-19 vaccine booster strategy: striving for best practice
Mine Durusu Tanrıöver, Murat Akova
The Lancet Global Health (2022) Vol. 10, Iss. 6, pp. e774-e775
Open Access | Times Cited: 7
China’s first mRNA vaccine is close — will that solve its COVID woes?
Yvaine Ye
Nature (2022)
Closed Access | Times Cited: 7
Omicron reactive multi protein specific CD4 T cells defines cellular immune response induced by inactivated virus vaccines
Joey Ming Er Lim, Shou Kit Hang, Smrithi Hariharaputran, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 4
Effectiveness of BNT162b2 and CoronaVac in children and adolescents against SARS-CoV-2 infection during Omicron BA.2 wave in Hong Kong
YL Lau, Daniel Leung, Jaime S. Rosa Duque, et al.
Research Square (Research Square) (2022)
Open Access | Times Cited: 4
Efficacy of Approved Versus Unapproved Vaccines for Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Randomized Blinded Clinical Trials
Andrea Perez Navarro, Victoria Pilkington, Toby Pepperrell, et al.
Open Forum Infectious Diseases (2022) Vol. 9, Iss. 9
Open Access | Times Cited: 3
Immunogenicity Against Wild-Type and Omicron SARS-CoV-2 After a Third Dose of Inactivated COVID-19 Vaccine in Healthy Adolescents
Daniel Leung, Carolyn A. Cohen, Xiaofeng Mu, et al.
SSRN Electronic Journal (2022)
Closed Access | Times Cited: 3
Safety and Immunogenicity of 3 Doses of BNT162b2 and CoronaVac in Children and Adults with Inborn Errors of Immunity
Daniel Leung, Xiaofeng Mu, Jaime S. Rosa Duque, et al.
Authorea (Authorea) (2022)
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top